<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160926</url>
  </required_header>
  <id_info>
    <org_study_id>09_DOG03_184</org_study_id>
    <secondary_id>2009-016524-31</secondary_id>
    <nct_id>NCT01160926</nct_id>
  </id_info>
  <brief_title>Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial</brief_title>
  <acronym>DREAMtherapy</acronym>
  <official_title>Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with&#xD;
      pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The best curative resection rates reported for patients with operable rectal cancer treated&#xD;
      with standard chemoradiotherapy are approximately 50-60%.The pathological complete response&#xD;
      rates are only 10-20%. Therefore, there is a need for more effective treatment. In this trial&#xD;
      we will evaluate the combination of chemoradiotherapy with either a VEGFR (vascular&#xD;
      endothelial growth factor receptor) or MEK (MAP Kinase)inhibitor.&#xD;
&#xD;
      Aims&#xD;
&#xD;
        1. Define the tolerability, MTD (maximum tolerated dose) and DLT (dose limiting toxicities)&#xD;
           of chemoradiotherapy in combination with&#xD;
&#xD;
             -  cediranib, a VEGF receptor tyrosine kinase inhibitor that inhibits angiogenesis or&#xD;
&#xD;
             -  AZD6244, a potent MEK inhibitor that inhibits cell proliferation&#xD;
&#xD;
        2. Define a dose suitable for phase II evaluation&#xD;
&#xD;
        3. Test the impact of the combination on soluble and imaging (FLT-PET and DCEMRI/DWI)&#xD;
           biomarkers to guide their use in phase II testing Summary Patients will receive standard&#xD;
           chemoradiotherapy plus ascending doses of AZD6244 or cediranib from day -10 (relative to&#xD;
           start of chemoradiotherapy) to day 35. If feasible, patients' tumours will be resected&#xD;
           10-12 weeks after treatment. Translational studies on available tissue and blood will be&#xD;
           performed and DCE-MRI/DWI and FLT-PET will be carried out on 5 patients in the expanded&#xD;
           cohort for AZD6244 (FLT-PET and DCE-MRI) and 5 patients in the expanded cohort for&#xD;
           cediranib (DCE-MRI).&#xD;
&#xD;
      Cohorts Cediranib - 15mg od, 20mg od and 30mg od AZD6244 - 50mg bd and 75mg bd&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    2 DLTs had been reported from first 4 patients on lowest possible dose cohort.&#xD;
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 4, 2016</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the MTD (maximum tolerated dose) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.</measure>
    <time_frame>At point of surgery (10-12 weeks post treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 toxicity</measure>
    <time_frame>Up to point of surgery and long-term effects monitored for 3 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy compliance</measure>
    <time_frame>for the 5 weeks of chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI (Magnetic Resonance Imaging)Response Rate</measure>
    <time_frame>8 weeks post chemoradiation - at point of MRI scan</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologically confirmed R0 resection rate</measure>
    <time_frame>10-12 weeks post chemoradiation - at time of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR)</measure>
    <time_frame>10-12 weeks post chemoradiation - at point of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity - post operative and long term</measure>
    <time_frame>3 years post chemoradiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore biological and radiological markers of response or toxicity</measure>
    <time_frame>Various timepoints up to point of surgery</time_frame>
    <description>Tissue samples - from diagnostic sample, biopsy 6-8 days after single agent AZD6244/Cediranib and resection sample from surgery.&#xD;
Blood samples - screening, weeks 1, 3 and 5 during chemoradiotherapy and 8 weeks post chemoradiotherapy.&#xD;
FLT-PET scans - patients in AZD6244 cohorts only - at screening, after 10 days of dosing with single agent AZD6244 and 2 weeks post chemoradiation DCE-MRI scans - patients in both groups - at screening, after 10 days of dosing with single agent AZD6244/Cediranib and 2 weeks post chemoradiation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>AZD6244 + capecitabine + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cediranib + capecitabine + radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244</intervention_name>
    <description>Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd&#xD;
Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy</description>
    <arm_group_label>AZD6244 + capecitabine + radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib (AZD2171)</intervention_name>
    <description>10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od&#xD;
Oral tablets</description>
    <arm_group_label>Cediranib + capecitabine + radiotherapy</arm_group_label>
    <other_name>AZD2171</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inc Criteria:&#xD;
&#xD;
          -  Histologically confirmed rectal adenocarcinoma&#xD;
&#xD;
          -  MRI (magnetic resonance imaging) and triphasic CT (computerised tomography) defined&#xD;
             locally advanced rectal cancer:&#xD;
&#xD;
               -  Mesorectal fascia involved or&#xD;
&#xD;
               -  Mesorectal fascia threatened or&#xD;
&#xD;
               -  Any T3 tumours &lt; 5cm from the anal verge&#xD;
&#xD;
          -  Primary resection unlikely to achieve clear margins&#xD;
&#xD;
          -  No previous chemotherapy or radiotherapy for rectal cancer&#xD;
&#xD;
          -  Bone marrow function: absolute neutrophil count â‰¥1.5 x109/l and platelet count &gt;100&#xD;
             x109/l&#xD;
&#xD;
          -  Hepatobiliary function: serum bilirubin &lt;1.5 x upper limit of normal (ULN); serum ALP&#xD;
             &lt;5 x ULN; serum transaminase (AST or ALT) &lt;2.5 x ULN&#xD;
&#xD;
          -  Renal function: Serum creatinine clearance &gt;50mL/min by either Cockcroft-Gault formula&#xD;
             or EDTA (ethylenediaminetetraacetic acid) clearance&#xD;
&#xD;
          -  ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0-1&#xD;
&#xD;
          -  Disease can be encompassed within a radical radiotherapy treatment volume&#xD;
&#xD;
          -  No pre-existing condition which would deter radiotherapy, e.g. fistulas, severe&#xD;
             ulcerative colitis, Crohn's disease, prior adhesions&#xD;
&#xD;
          -  For women of child-bearing potential a negative pregnancy test is required and&#xD;
             adequate contraceptive precautions such as a condom for their partner must be used.&#xD;
             For men - adequate contraception must be used.&#xD;
&#xD;
          -  Fit to receive all study treatments&#xD;
&#xD;
          -  Able to comply with oral medication and protocol&#xD;
&#xD;
          -  Signed, written and dated informed consent.&#xD;
&#xD;
          -  Life expectancy â‰¥ 3 months.&#xD;
&#xD;
        Exc Criteria:&#xD;
&#xD;
          -  Concurrent uncontrolled medical illness, or other previous/current malignant disease&#xD;
             likely to interfere with protocol treatments&#xD;
&#xD;
          -  Age&lt;18&#xD;
&#xD;
          -  Any pregnant, lactating women or potentially childbearing patients not using adequate&#xD;
             contraception&#xD;
&#xD;
          -  Previous chemotherapy or radiotherapy for rectal cancer&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  ECOG PS&gt;1&#xD;
&#xD;
          -  Patients who have very significant small bowel delineated within the radiation fields.&#xD;
&#xD;
          -  Current or impending rectal obstruction (unless defunctioning stoma present), metallic&#xD;
             colonic rectal stent in situ&#xD;
&#xD;
          -  Pelvic sepsis.&#xD;
&#xD;
          -  Uncontrolled cardiac, respiratory or other disease, or any serious medical or&#xD;
             psychiatric disorder that would preclude trial therapy or informed consent.&#xD;
&#xD;
          -  Cardiac conditions as follows:&#xD;
&#xD;
               -  Uncontrolled hypertension (resting BP â‰¥150/95mmHg despite optimal therapy)&#xD;
&#xD;
               -  Heart failure NYHA Class II or above&#xD;
&#xD;
               -  Prior or current cardiomyopathy&#xD;
&#xD;
               -  Atrial fibrillation with heart rate &gt;100 bpm&#xD;
&#xD;
               -  Unstable ischaemic heart disease&#xD;
&#xD;
          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, or significant&#xD;
             bowel resection that would preclude adequate absorption of trial drug&#xD;
&#xD;
          -  Patients who are deemed unsuitable for surgery because of co-morbidity or coagulation&#xD;
             problems.&#xD;
&#xD;
          -  Recent (&lt;14 days) major thoracic or abdominal surgery prior to entry into the study or&#xD;
             a surgical incision that is not fully healed which would prevent administration of&#xD;
             study treatment&#xD;
&#xD;
          -  Known DPD (dihydropyrimidine dehydrogenase)deficiency&#xD;
&#xD;
          -  Patients suffering from any condition that may affect the absorption of capecitabine&#xD;
             or IMP (investigational medical product)&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease, active infection, active&#xD;
             bleeding diatheses or renal transplant, including any patient known to have Hep B, Hep&#xD;
             C or HIV&#xD;
&#xD;
          -  Mean QTc with Bazetts correction &gt;470msec in screening ECG or history of familial long&#xD;
             QT syndrome&#xD;
&#xD;
        EXC CRITERIA (AZD6244 cohorts)&#xD;
&#xD;
          -  KRAS (Kirsten ras sarcoma viral oncogene) wild-type&#xD;
&#xD;
          -  Prior treatment with a MEK inhibitor&#xD;
&#xD;
          -  Baseline LVEF (left ventricular ejection fraction) â‰¤50%&#xD;
&#xD;
        EXC CRITERIA (Cediranib cohorts)&#xD;
&#xD;
          -  Known hypersensitivity to Cediranib or any of its excipients&#xD;
&#xD;
          -  Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week&#xD;
             apart unless urinary protein &lt; 1.5g in a 24 hr period or protein/creatinine ratio &lt;&#xD;
             1.5.&#xD;
&#xD;
          -  Significant haemorrhage (&gt;30mL bleeding/episode in previous 3 months) or haemoptysis&#xD;
             (&gt;5mL fresh blood in previous 4 weeks)&#xD;
&#xD;
          -  APTT ratio &gt; 1.5 x ULN&#xD;
&#xD;
          -  Arterial thromboembolic event (including ischemic attack) in the previous 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark P Saunders, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2010</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>capecitabine</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>AZD6244</keyword>
  <keyword>MEK inhibitor</keyword>
  <keyword>AZD2171</keyword>
  <keyword>Cediranib</keyword>
  <keyword>VEGFR inhibitor</keyword>
  <keyword>FLT-PET (fluoro-l-pyrimidine positron emission tomography)</keyword>
  <keyword>DCE-MRI (dynamic contrast enhanced magnetic resonance imaging)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

